BNP Paribas Financial Markets
GENE

BNP Paribas Financial Markets’s Genetic Technologies Ltd. GENE Stock Holding History

BNP Paribas Financial Markets’s Portfolio GENE Stock Details GENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,300
Closed – – 6198
2025
Q4 		$0 Buy
+15,300
New – ﹤0.01% 6018
2024
Q4 		– Sell
-15,100
Closed -$11.7K – 5596
2024
Q3 		$11.7K Buy
15,100
+2,500
+20% +$2.22K ﹤0.01% 3793
2024
Q2 		$18.9K Buy
12,600
+3,500
+38% +$7.87K ﹤0.01% 3648
2024
Q1 		$26.3K Buy
+9,100
New +$20.9K ﹤0.01% 3631

Other funds holding GENE

RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

BNP Paribas Financial Markets's GENE Position: Q1 2026 in Review

BNP Paribas Financial Markets sold out of Genetic Technologies Ltd. (GENE) in Q1 2026, closing a stake of 15,300 shares.

BNP Paribas Financial Markets first reported a position in GENE in Q1 2024 and held it in 4 quarters. The position peaked at $26.3K in Q1 2024. 1 fund tracked by Wall St. Rank holds GENE as of Q1 2026.

  • BNP Paribas Financial Markets reported no remaining Genetic Technologies Ltd. position as of Q1 2026 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 15,300 Genetic Technologies Ltd. shares in Q1 2026.
  • BNP Paribas Financial Markets first reported a position in Genetic Technologies Ltd. in Q1 2024 and held it in 4 quarters.
  • BNP Paribas Financial Markets's Genetic Technologies Ltd. position peaked at $26.3K in Q1 2024.
  • 1 fund tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.